We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $2.19B
1-Year Est. Return 374.99%
This Fund
S&P 500
This Quarter Est. Return
+8.25%
1 Year Est. Return
+374.99%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.7B
AUM Growth
+$337M
Cap. Flow
+$308M
Cap. Flow %
18.12%
Top 10 Hldgs %
39.64%
Holding
351
New
78
Increased
102
Reduced
60
Closed
41

Top Buys

Rank Stock Value
1
BEAM icon
Beam Therapeutics
BEAM
+$40.1M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$37.1M
3
DNLI icon
Denali Therapeutics
DNLI
+$36.2M
4
INSP icon
Inspire Medical Systems
INSP
+$27.3M
5
VIR icon
Vir Biotechnology
VIR
+$21.9M

Top Sells

Rank Stock Value
1
RNAM
Avidity Biosciences
RNAM
+$39.4M
2
RAPT
RAPT Therapeutics
RAPT
+$17.3M
3
CDTX
Cidara Therapeutics
CDTX
+$13.2M
4
FULC icon
Fulcrum Therapeutics
FULC
+$10.4M
5
ABUS icon
Arbutus Biopharma
ABUS
+$9.98M

Sector Composition

Rank Sector Weight
1 Healthcare 88.42%
2 Miscellaneous 9.68%
3 Financials 1.51%
4 Technology 0.08%
5 Industrials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RLMD icon
101
Relmada Therapeutics
RLMD
$462M
$3.15M 0.19%
451,918
+421,052
+1,364% +$1.99M
CATX icon
102
Perspective Therapeutics
CATX
$355M
$3.12M 0.18%
749,335
+654,142
+687% +$2.76M
CRBP icon
103
Corbus Pharmaceuticals
CRBP
$211M
$3.12M 0.18%
331,781
+45,000
+16% +$379K
ELDN icon
104
Eledon Pharmaceuticals
ELDN
$260M
$3M 0.18%
974,421
-847,391
-47% -$2M
PHVS icon
105
Pharvaris
PHVS
$2.48B
$2.98M 0.18%
105,528
+20,000
+23% +$534K
APLS
106
DELISTED
Apellis Pharmaceuticals
APLS
$2.92M 0.17%
72,500
+52,500
+263% +$1.13M
EWTX icon
107
Edgewise Therapeutics
EWTX
$4.64B
$2.85M 0.17%
90,599
-400
-0.4% -$11.5K
PEPG icon
108
PepGen
PEPG
$213M
$2.85M 0.17%
1,607,638
+1,570,796
+4,264% +$8.83M
CAPR icon
109
Capricor Therapeutics
CAPR
$558M
$2.75M 0.16%
+90,593
New +$2.41M
MASI
110
DELISTED
Masimo
MASI
$2.67M 0.16%
15,000
– –
INO icon
111
Inovio Pharmaceuticals
INO
$133M
$2.56M 0.15%
1,470,108
-14,900
-1% -$24.5K
TFX icon
112
Teleflex
TFX
$5.92B
$2.53M 0.15%
21,186
-59,441
-74% -$6.55M
DRUG
113
Bright Minds Biosciences
DRUG
$714M
$2.47M 0.15%
33,900
+30,400
+869% +$2.45M
BIOA
114
BioAge Labs
BIOA
$443M
$2.37M 0.14%
135,560
– –
ALEC icon
115
Alector
ALEC
$261M
$2.26M 0.13%
1,050,000
-58,000
-5% -$116K
PFE icon
116
Pfizer
PFE
$159B
$2.17M 0.13%
77,400
+5,000
+7% +$133K
DCTH icon
117
Delcath Systems
DCTH
$567M
$2.08M 0.12%
224,385
– –
BIIB icon
118
Biogen
BIIB
$32.3B
$2.02M 0.12%
11,000
-13,300
-55% -$2.45M
CNTB
119
Connect Biopharma Holdings
CNTB
$140M
$1.95M 0.11%
+742,400
New +$1.94M
XBI icon
120
PUT
State Street SPDR S&P Biotech ETF
XBI
$11.3B
$1.92M 0.11%
+15,000
New +$1.87M
SMMT icon
121
Summit Therapeutics
SMMT
$11B
$1.74M 0.1%
91,869
– –
GMED icon
122
Globus Medical
GMED
$11.1B
$1.73M 0.1%
20,100
– –
ALKS icon
123
Alkermes
ALKS
$7.95B
$1.64M 0.1%
46,400
-17,300
-27% -$537K
QURE icon
124
CALL
uniQure
QURE
$3.38B
$1.64M 0.1%
100,000
+70,000
+233% +$1.42M
SLNO
125
DELISTED
Soleno Therapeutics
SLNO
$1.57M 0.09%
46,830
+5,000
+12% +$196K
3 4
5
6 7

Similar funds

GAMH
Greenwoods Asset Management (HK) Hong Kong $2.19B AUM 50.16% 1-Year Est. Return
RCAG
Rehmann Capital Advisory Group Lansing, Michigan $2.18B AUM 23.73% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $2.19B AUM 21.28% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $2.19B AUM 23.13% 1-Year Est. Return
TCM
Traynor Capital Management Malvern, Pennsylvania $2.18B AUM 62.36% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $2.18B AUM 13.58% 1-Year Est. Return
IAN
Integrated Advisors Network Dallas, Texas $2.18B AUM 30.3% 1-Year Est. Return
BOI
Bank of Italy Rome, Italy $2.2B AUM 1.53% 1-Year Est. Return

ADAR1 Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, ADAR1 Capital Management held 351 positions worth $1.7B, up 25% from $1.36B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

ADAR1 Capital Management deployed $308M of net new capital in Q1 2026, opening 78 new positions and adding to 102 existing holdings. Its largest new stake was Beam Therapeutics: 1,446,375 shares worth $34.5M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 89% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Fulcrum Therapeutics, an estimated $10.4M trimmed.

  • ADAR1 Capital Management's largest Q1 2026 buy was Beam Therapeutics: 1,446,375 shares worth $34.5M.
  • ADAR1 Capital Management added most to Crinetics Pharmaceuticals in Q1 2026, an estimated $37.1M increase.
  • ADAR1 Capital Management's biggest Q1 2026 reduction was Fulcrum Therapeutics, cutting an estimated $10.4M.
  • ADAR1 Capital Management fully exited Avidity Biosciences in Q1 2026, selling an estimated $39.4M.
  • ADAR1 Capital Management's ten largest holdings make up 40% of its $1.7B portfolio in Q1 2026.
  • ADAR1 Capital Management opened 78 new positions and closed 41 in Q1 2026.
  • ADAR1 Capital Management's portfolio value rose 25% quarter-over-quarter to $1.7B.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.